知镜 Cognispect · 医学文献与研究工作台

Effects of PCSK9 inhibitors on coronary atheroma morphology in patients with coronary artery disease treated with statins: a meta-analysis and systematic review.

Thakurathi P, Kim AS, Nanna MG, Dahal K, Aryal SS, Pack Q, Kalra DK, McKay RG, Thompson PD, Goldsweig AM.
American journal of preventive cardiology · 2026-06-29 · PMID 42827838

文献摘要

Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce adverse cardiovascular events when added to statins, but their effects on coronary plaque morphology remain inadequately defined. Methods We searched PubMed via MEDLINE, Cochrane CENTRAL, Scopus, Web of Science for randomized controlled trials comparing the effects of PCSK9i plus statins versus statins alone on coronary atheroma morphology in patients with coronary artery disease, including total atheroma volume (TAV), percent atheroma volume (PAV), fibrous cap thickness (FCT), minimal lumen area (MLA), maximum lipid arc (MLArc), and lipid parameters. Random-effects models pooled mean differences (MDs). Results Of 1,472 abstracts screened, eight randomized controlled trials ( n = 1,898; PCSK9i+statin n = 950; statins alone n = 948) met inclusion criteria with mean follow-up of 59.4 ± 21.4 weeks. Compared with statins alone, PCSK9i plus statins increased FCT (MD 26.48 um, 95% CI 14.00 to 38.96) and reduced MLArc (MD -16.97°, 95% CI -30.90 to -3.04). In IVUS studies, PCSK9i reduced PAV (MD -0.86%, 95% CI -1.16 to -0.55) and TAV (MD -8.95 mm 3 , 95% CI -15.81 to -2.10); MLA did not differ. PCSK9i also produced larger reductions in LDL-C, total cholesterol, non-HDL-C, triglycerides, ApoB, and Lp(a), with a modest increase in HDL-C. Conclusions The addition of PCSK9i to statin therapy improved coronary atheroma composition and morphology in patients with coronary artery disease.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。